SCHOTT Pharma Reports Solid H1 2026 Performance Driven by Strong Demand for Specialized Injectable Solutions

Reinhard Mayer, CFO, and Dr. Christian Mias, CEO of SCHOTT Pharma. Image: SCHOTT Pharma/Johannes Schembs

(IN BRIEF) SCHOTT Pharma delivered a resilient performance during the first half of fiscal year 2026, reporting revenue growth despite ongoing market challenges and maintaining strong profitability. The company benefited from continued demand for high-value pharmaceutical containment products, especially sterile cartridges, specialty vials, and prefillable glass syringes for GLP-1 therapies. Although declining mRNA vaccination demand negatively affected polymer syringe sales, SCHOTT Pharma maintained stable earnings overall while significantly improving free cash flow through stronger receivables management. The company also continued investing heavily in manufacturing expansion projects in Switzerland and Hungary and announced the upcoming launch of its new cartriQ® BioPure platform for biologics and self-administration systems. With its focus on high-margin high-value solutions and growing pharmaceutical demand, SCHOTT Pharma confirmed its full-year 2026 outlook for revenue growth and profitability.

(PRESS RELEASE) MAINZ, 13-May-2026 — /EuropaWire/ — SCHOTT Pharma, a global developer of drug containment solutions and delivery systems for injectable therapies, delivered a stable financial performance during the first half of fiscal year 2026 despite ongoing global market challenges, while significantly improving free cash flow and maintaining its full-year outlook.

For the six-month period ending March 31, 2026, the company generated revenue of EUR 488.1 million, representing growth of 2.3% at constant currencies and 1.0% on a reported basis. SCHOTT Pharma continued to expand the contribution of its high-value solutions (HVS), which accounted for 56% of total sales compared with 55% during the same period last year. EBITDA remained largely stable at EUR 129.8 million, translating into an EBITDA margin of 26.6%, slightly below the 27.0% reported in the prior-year period.

The company’s newly appointed CEO, Christian Mias, who assumed leadership in May 2026, said the business performed in line with expectations and demonstrated resilience in a demanding economic environment. He highlighted the company’s strategic emphasis on high-margin high-value solutions as a key factor supporting operational stability and reaffirmed the company’s confidence in achieving its full-year guidance.

Reinhard Mayer noted that the company continued to grow profitably while investing in additional manufacturing capacity to address sustained customer demand and strengthen its technological leadership. He also pointed to improvements in receivables management, which contributed to a substantial rise in free cash flow and reinforced the company’s financial position.

Within the Drug Containment Solutions (DCS) division — which includes glass vials, cartridges, and ampoules used for injectable medications — revenue increased to EUR 286.4 million. This represented growth of 8.3% at constant currencies and 5.7% on a reported basis. Demand remained especially strong for sterile cartridges, specialty vials, and high-end containment products. High-value solutions in the segment expanded to 25% of sales, up from 20% a year earlier. EBITDA for the segment climbed 17.2% to EUR 71.8 million, supported by favorable product mix and volume growth, while the EBITDA margin improved to 25.1% from 22.6% in the previous year.

The Drug Delivery Systems (DDS) segment, which focuses on glass and polymer syringes, generated revenue of EUR 201.8 million. Sales declined by 5.4% at constant currencies compared with the prior-year period, mainly due to lower demand for polymer syringes linked to declining mRNA vaccination volumes. However, strong demand for prefillable glass syringes used in GLP-1 therapies partially offset this decline. Earnings in the DDS segment were impacted by lower production utilization and a one-time impairment related to customer-specific glass syringes. Segment EBITDA fell 18.0% to EUR 59.5 million, resulting in a margin of 29.5%. Excluding the one-off impairment effect, profitability would have remained close to the previous year’s margin level.

SCHOTT Pharma also reported a marked improvement in cash generation during the period. Cash flow from operating activities reached EUR 95.1 million, increasing by EUR 22.5 million year-over-year. Free cash flow more than doubled to EUR 45.4 million, driven largely by stronger receivables management and operational efficiencies.

The company continued investing in production expansion projects across both business segments, particularly in facilities located in Switzerland and Hungary, where additional capacity is being added to support growing demand for specialized pharmaceutical containment products. Capital expenditures totaled EUR 50.1 million during the first half, remaining broadly in line with the previous year.

In April 2026, SCHOTT Pharma introduced plans to launch its new cartriQ® BioPure platform toward the end of the year. The advanced glass cartridge is designed specifically for complex biologics and integration into self-administration systems, further strengthening the company’s portfolio of high-value pharmaceutical packaging and delivery solutions.

Looking ahead, SCHOTT Pharma reaffirmed the financial guidance issued in December 2025. The company continues to expect revenue growth at constant currencies in the range of 2% to 5% for fiscal year 2026, alongside an EBITDA margin of around 27%.

The key figures for Q2 and H1 can be found here.

Webcast

Christian Mias (CEO) and Reinhard Mayer (CFO) will present the results for the second quarter and first half of 2026 during a conference call for analysts and investors on May 13, 2026, at 11:00 a.m. CEST. The audio webcast can be followed via the following link. The accompanying presentation is available on our IR website.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Further information at www.schott-pharma.com

Media Contact:

Katrin Schreyer
Manager Global Communications Investor Relations Pharma
+496131664932

SOURCE: SCHOTT Pharma